Modalis Therapeutics (TSE:4883) Beneish M-Score: 0.00 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4883 Modalis Therapeutics Corp TSE:4883
20 GF Score
Price 円34.00
! 2 Warning Signs
View Full Analysis

What is Modalis Therapeutics Beneish M-Score?

Modalis Therapeutics TSE:4883 +3.03% 20 Beneish M-Score is 0.00 as of Jul. 14, 2026. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 911 Drug Manufacturers companies, Modalis Therapeutics ranks worse than 109769.37% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Modalis Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 8 years, the highest Beneish M-Score of Modalis Therapeutics was 27.84. The lowest was -63.04. And the median was 9.25.


Modalis Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Modalis Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modalis Therapeutics Beneish M-Score Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -63.04 27.84 0.00 0.00 0.00

Modalis Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4883 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modalis Therapeutics Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's Beneish M-Score falls into.


TSE:4883
20GF Score
Modalis Therapeutics Corp TSE:4883
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modalis Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Modalis Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was 円0.00 Mil.
Revenue was 円0.00 Mil.
Gross Profit was 円0.00 Mil.
Total Current Assets was 円2,892.27 Mil.
Total Assets was 円2,964.25 Mil.
Property, Plant and Equipment(Net PPE) was 円0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was 円0.00 Mil.
Selling, General, & Admin. Expense(SGA) was 円231.81 Mil.
Total Current Liabilities was 円134.80 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.
Net Income was 円-2,152.71 Mil.
Gross Profit was 円0.00 Mil.
Cash Flow from Operations was 円-2,118.41 Mil.
Total Receivables was 円0.00 Mil.
Revenue was 円0.00 Mil.
Gross Profit was 円0.00 Mil.
Total Current Assets was 円3,617.08 Mil.
Total Assets was 円3,691.55 Mil.
Property, Plant and Equipment(Net PPE) was 円0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was 円0.00 Mil.
Selling, General, & Admin. Expense(SGA) was 円245.48 Mil.
Total Current Liabilities was 円117.32 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0) / (0 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2892.272 + 0) / 2964.248) / (1 - (3617.079 + 0) / 3691.549)
=0.024281 / 0.020173
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 0)) / (0 / (0 + 0))
= /
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(231.807 / 0) / (245.476 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 134.802) / 2964.248) / ((0 + 117.322) / 3691.549)
=0.045476 / 0.031781
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2152.71 - 0 - -2118.409) / 2964.248
=-0.011572

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Modalis Therapeutics (TSE:4883) has a Beneish M-Score of 0.00 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Modalis Therapeutics and its competitors. According to the industry distribution chart, Modalis Therapeutics ranks #999999 out of 911 companies in the Drug Manufacturers industry.
Is Modalis Therapeutics' Beneish M-Score too high?
Modalis Therapeutics' current Beneish M-Score is 0.00. Based on the distribution chart, Modalis Therapeutics ranks #999999 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Modalis Therapeutics ranks #999999 out of 911 companies for Beneish M-Score. This places Modalis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Modalis Therapeutics and its competitors. Modalis Therapeutics's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current Beneish M-Score is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modalis Therapeutics Business Description

Address 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score

Get the complete analysis for TSE:4883

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円34.00
Price